Race modifies the association between breast carcinoma pathologic prognostic idicators and the positive status for HER-2/neu

Cancer

Volumn 104, Issue 10, 2005, Pages 2189-2196

  Stark, Azadeh T ^a,c   Claud, Sarah ^a   Kapke, Alissa ^a   Lu, Mei ^a   Linden, Michael ^a   Griggs, Jennifer ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Josephine Ford Cancer Center   (United States)

Author keywords

African American; Breast carcinoma; Caucasian; Ethnicity; HER 2 neu; Race

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RISK; CANCER STAGING; CAUCASIAN; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE;

AFRICAN AMERICANS; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PREVALENCE; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 27644465849     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21463     Document Type: Article

References (34)

1. Salmon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Andrulis IL, Bull SB, Blackstein ME, et al. Neu/ErB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16:1340-1349.
3. Tetu B, Brisson J. Prognostic significance of HER-2/neu positive breast carcinoma as a particular subset with peculiar clinical behavior. Clin Cancer Res. 2002;8:520-525.
4. Carlomagno C, Perrone F, Gallo C, et al. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.
5. Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on Her-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res. 2001;7:1577-1581.
6. Funkhouser WK, Kaiser-Rogers K. Significance of, and optimal screening for, Her-2 gene amplification and protein overexpression in breast carcinoma [Review]. Ann Clin Lab Sci. 2001;31:349-357.
7. Hanna W, Kahn HGJ, Trudeau M. Evaluation of the HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Med Pathol. 1999;12:827-834.
8. Dignam JJ, Redmond CK, Fisher B, et al. Prognosis among African-American women and white women with lymph node negative breast carcinoma. Findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer. 1997;80:80-90.
9. Dignam JJ. Differences in breast cancer prognosis among African-American and Caucasian women. CA-Cancer J Clin. 2000;50:50-64.
10. Jones LA, Brawley O, Johnson-Thompson M, et al. Overview of the summit meeting evaluating research in African-American women. Cancer. 2003;97:207-210.
11. Newman LA, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival. A meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer. 2002;94:2844-2854.
12. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer. 2000;88:114-123.
13. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat. 2002;73:45-59.
14. Gapstur SM, Dupuis J, Gann P, et al. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic women. An analysis of 13,239 cases. Cancer. 1996;77: 1465-1471.
15. Beverly LN, Flanders WD, GO RCP, et al. A comparison of estrogen and progesterone receptors in black and white breast cancer patients. Am J Public Health. 1987;77:351-353.
16. Joslyn SA. Racial differences in treatment and survival from early stage breast carcinoma. Cancer. 2002;95:1759-1766.
17. Alexieva-Figusch J, Van Putten WI, Blankenstein MA, et al. The prognostic value and relationships of patient characteristics, estrogen and progesterone receptors, and site of relapse in primary breast cancer. Cancer. 1988;61:758-768.
18. Newman LA, Bunner S, Carolin K, et al. Ethnicity related differences in the survival of young breast carcinoma patients. Cancer. 2002;95:21-27.
19. Weiss SE, Tamer PI, Ahmed S, et al. Ethnic differences in risk and prognostic factors for breast cancer. Cancer. 1995; 76:268-274.
20. Elledge RM, Clark GM, Chamness GC, et al. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86:705-712.
21. Hosmer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1997.
22. Wu Y, Khan H, Chillar R, et al. Prognostic value of plasma HER-2/new in African-American and Hispanic women with breast cancer. Int J Oncol. 1999;14:1021-1037.
23. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.
24. Taucher S, Rudas M, Mader RM, et al. Do we need HER-2/ neu testing for all patients with primary breast carcinoma? Cancer. 2003;98:2547-2453.
25. Wojcik BE, Spinks MK, Optenberg SA. Breast carcinoma survival analysis for African-American and white women in an equal-access healthcare system. Cancer. 1998;82:1310-1318.
26. Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U.S. Department of Defense healthcare system. Cancer. 2003;98:894-899.
27. Griggs JJ, Sorbero ME, Stark A, et al. Racial/ethnic disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81:21-31.
28. Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle regulator proteins in breast carcinoma. Study of young African-American and white women in Atlanta, Georgia. Cancer. 2004;100:2533-2542.
29. Jones BA, Kasi SV, Howe CL, et al. African American/white differences in breast carcinoma. P53 alterations and other tumor characteristics. Cancer. 2004;101:1293-1301.
30. Poola I, Clarke R, DeWitty R, et al. Functionally active estrogen receptor isoform profiles in the breast tumors of African-American women are different from the profiles in breast tumors of Caucasian women. Cancer. 2002;94:615-623.
31. Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002;94:471-473.
32. Gordon NH. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemol. 1995;142:796-803.
33. Murthy VH, Krumholz HM, Gross GP. Participation in cancer clinical trials. Race-, sex- and age-based disparities. JAMA. 2004;291:2720-2726.
34. National Institutes of Health. http://www4.od.nih.gov/ orwh/revitalization.pdf [accessed Nov 15, 2004].